Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 05, 2020 08:00 ET | Source: Tyme Technologies, Inc.

TYME Announces Third Quarter Fiscal 2020 Financial and Operating Results

Strategic collaboration with Eagle Pharmaceuticals entitles TYME to receive up to a total of $40 million, which included $20 million upfront already received and $20 million in potential milestone...
January 27, 2020 08:00 ET | Source: Tyme Technologies, Inc.

Health Economic Research Study Demonstrates Increased Use of New Medicines in the Treatment of Patients with Pancreatic Cancer Reduces Total Cost of Care

The study shows that for every additional $1 spent on innovative medicines for pancreatic cancer between 2009 to 2016, there was a reduction in non-medicine spending of $8 to $9 This preliminary...
January 16, 2020 08:00 ET | Source: Tyme Technologies, Inc.

TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas

New oral approach aimed at disrupting cancer metabolism in high-risk sarcomas; 12,000 cases annually in U.S. aloneOral SM-88 represents a new approach designed to selectively disrupt protein synthesis...
January 08, 2020 08:00 ET | Source: Tyme Technologies, Inc.

TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic Pancreatic Cancer

Oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers - demonstrated responses in 15 different cancer types across four separate studiesData presented at...
December 04, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies to Present at the 2019 Cross-Border Healthcare Winter Summit in New York

NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
November 25, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME to Ring Nasdaq Opening Bell on November 27 to Honor All Stakeholders Committed to Finding a Cure for Patients with Pancreatic Cancer

Pancreatic Cancer Expected to be the Second Leading Cause of Cancer-Related Death in the U.S. by 20201TYME’s oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in...
November 21, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies to Present at the Evercore ISI HealthCONx Conference 2019

NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
November 07, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies to Present at Jefferies 2019 London Healthcare Conference on November 20-21, 2019

NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
November 04, 2019 16:05 ET | Source: Tyme Technologies, Inc.

TYME Presents Business Update and Reports Second Quarter Fiscal 2020 Financial and Operating Results

Quarterly conference call today, November 4th, at 5 p.m. Eastern TimeUpdated Data From TYME-88-Panc PET Imaging and TYME-18 Preclinical Studies on Conference CallExpect Enrollment of Patients in the...
October 17, 2019 16:05 ET | Source: Tyme Technologies, Inc.

TYME Presents Business Update and Announces Second Quarter Fiscal 2020 Conference Call and Preliminary Operational Results

TYME Launched the Pivotal Stage of TYME-88-PANC Trial to Evaluate Oral SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic CancerTYME Presented Final Data at ESMO 2019 from SM-88...